KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$420.9 million.

  • Gsk's Tax Provisions fell 3249458.74% to -$420.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 billion, marking a year-over-year decrease of 2065.01%. This contributed to the annual value of $672.4 million for FY2024, which is 2849.61% down from last year.
  • As of Q3 2025, Gsk's Tax Provisions stood at -$420.9 million, which was down 3249458.74% from -$321.5 million recorded in Q2 2025.
  • Over the past 5 years, Gsk's Tax Provisions peaked at $280.9 million during Q2 2021, and registered a low of -$938.3 million during Q4 2023.
  • In the last 5 years, Gsk's Tax Provisions had a median value of -$325.5 million in 2023 and averaged -$324.8 million.
  • In the last 5 years, Gsk's Tax Provisions skyrocketed by 21256.61% in 2021 and then tumbled by 3249458.74% in 2025.
  • Gsk's Tax Provisions (Quarter) stood at $157.7 million in 2021, then plummeted by 625.79% to -$829.3 million in 2022, then dropped by 13.15% to -$938.3 million in 2023, then increased by 28.05% to -$675.1 million in 2024, then soared by 37.66% to -$420.9 million in 2025.
  • Its last three reported values are -$420.9 million in Q3 2025, -$321.5 million for Q2 2025, and -$423.2 million during Q1 2025.